Related Experiment Video

Updated: Mar 26, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

Impact of Imatinib Adherence on the Cytogenetic Response in Pediatric Chronic Myeloid Leukemia - Chronic Phase

Ranga Raman Ganta1, Srividya Nasaka1, Sadashivudu Gundeti2

  • 1Department of Medical Oncology, Nizams Institute of Medical Sciences, Hyderabad, Telangana, 500082, India.

Indian Journal of Pediatrics
|February 5, 2016
PubMed

Insights

Adherence to imatinib in pediatric chronic myeloid leukemia (CML) significantly improves cytogenetic response. Children who adhered to imatinib treatment achieved optimal responses, unlike non-adherent patients.

Area of Science:

  • Hematology
  • Pediatric Oncology
  • Pharmacology

Background:

  • Pediatric chronic myeloid leukemia (CML) requires long-term treatment.
  • Imatinib is a key therapy for CML, but adherence can be challenging in pediatric patients.
  • Understanding the impact of adherence on treatment outcomes is crucial for optimizing pediatric CML management.

Purpose of the Study:

  • To investigate the association between adherence to imatinib therapy during the first six months and cytogenetic response in pediatric patients with CML in chronic phase (CML CP).

Main Methods:

  • Retrospective analysis of hospital records for pediatric CML patients (age ≤18 years) from 2009-2012.
  • Evaluation of imatinib adherence and cytogenetic response (CyR) at six months.
  • Analysis included 48 children with varying Sokal scores.

Main Results:

  • Only 58% of pediatric CML patients demonstrated adherence to imatinib.
  • Complete cytogenetic response (CCyR) was achieved by 78.5% of adherent children versus only 5% of non-adherent children at six months.
  • 80% of non-adherent children achieved only partial cytogenetic response (PCyR).

Conclusions:

  • High adherence to imatinib in pediatric CML patients is strongly correlated with optimal cytogenetic response at six months.
  • Non-adherence significantly hinders the achievement of desired cytogenetic responses in pediatric CML.
  • Ensuring imatinib adherence is critical for improving treatment outcomes in children with CML CP.

Keywords:
CML CPCytogenetic response at 6 moImatinib adherence

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

905

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
67
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
369